ALK and non-small cell lung carcinoma: The first FDA-approved ALK inhibitor for ALK-positive metastatic NSCLC treatment in 2011, crizotinib, has shown significant improvement in progression-free survival (PFS) and tumor responses in patients with metastatic NSCLC who carry the ALK gene rearrangement [9].